Evidence map›Paper›PMID 18809815›Full record

ArticleArchives of internal medicine2008

Trade-offs in cervical cancer prevention: balancing benefits and risks.

Natasha K Stout, Jeremy D Goldhaber-Fiebert, Jesse D Ortendahl, Sue J Goldie

Abstract read
In one paragraph

Article in Archives of internal medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs.Medical decision making : an international journal of the Society for Medical Decision Making · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Improving compliance with cervical cancer screening guidelines.Proceedings (Baylor University. Medical Center) · 2015
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Screening adolescents and young women.Obstetrics and gynecology clinics of North America · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Natasha K StoutProgram in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115, USA. natasha_stout@hms.harvard.edu
Jeremy D Goldhaber-Fiebert
Jesse D Ortendahl
Sue J Goldie

Funding

Clinical & Cost Effectiveness of HPV Vaccination in the USR01CA093435 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI GOLDIE, SUE J · 2002 to 2009
$2.4M
NCI NIH HHS R01 CA093435
6 · The paper itself

Abstract

backgroundNew screening and vaccination technologies will provide women with more options for cervical cancer prevention. Because the risk of cervical cancer diminishes with effective routine screening, women may wish to consider additional attributes, such as the likelihood of false-positive results and diagnostic procedures for mild abnormalities likely to resolve without intervention in their screening choices.

methodsWe used an empirically calibrated simulation model of cervical cancer in the United States to assess the benefits and potential risks associated with prevention strategies differing by primary screening test, triage test for abnormal results (cytologic testing, human papillomavirus [HPV] DNA test), and screening frequency. Outcomes included colposcopy referrals, cervical intraepithelial neoplasia (CIN) types 1 and 2 or 3, lifetime cancer risk, and quality-adjusted life expectancy.

resultsAcross strategies, colposcopy referrals and diagnostic workups varied 3-fold, although diagnostic rates of CIN 2 or 3 were similar and 95% of positive screening test results were for mild abnormalities likely to resolve on their own. For a representative group of a thousand 20-year-old women undergoing triennial screening for 10 years, we expect 1038 colposcopy referrals (7 CIN 2 or 3 diagnoses) from combined cytologic and HPV DNA testing and fewer than 200 referrals (6-7 CIN 2 or 3 diagnoses) for strategies that use triage testing. Similarly, for a thousand 40-year-old women, combined cytologic and HPV DNA testing led to 489 referrals (9 CIN 2 or 3), whereas alternative strategies resulted in fewer than 150 referrals (7-8 CIN 2 or 3). Using cytologic testing followed by triage testing in younger women minimizes both diagnostic workups and positive HPV test results, whereas in older women diagnostic workups are minimized with HPV DNA testing followed by cytologic triage testing.

conclusionsClinically relevant information highlighting trade-offs among cervical cancer prevention strategies allows for inclusion of personal preferences into women's decision making about screening and provides additional dimensions to the construction of clinical guidelines.

Indexed as

AdultColposcopyDecision MakingDNA Probes, HPVFalse Positive ReactionsFemaleHumansLife ExpectancyModels, TheoreticalQuality of LifeReferral and ConsultationSensitivity and SpecificityTriageUterine Cervical DysplasiaUterine Cervical NeoplasmsDNA Probes, HPV

Identifiers

PMID18809815
PMCPMC2746633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.